Volume 17, Number 3—March 2011
Research
Targeted Drug-Resistance Testing Strategy for Multidrug-Resistant Tuberculosis Detection, Lima, Peru, 2005–2008
Table 5
Risk factor | Total no. patients | No. (%) MDR TB | Odds ratio (95% CI) |
---|---|---|---|
Previously treated smear-positive TB patients in NTP regional surveillance data | 104 | 25 (24.0) | |
Previously treated smear-positive TB patients in study cohort | 583 | 210 (36.0) | 1.78 (1.10–2.88) |
HIV positive | 36 | 12 (33.3) | 1.58 (0.69–3.61) |
Diabetes mellitus | 30 | 10 (33.3) | 1.58 (0.65–3.82) |
Adverse reaction | 13 | 1 (7.7) | 0.26 (0.01–1.97) |
Previous hospitalization within the past 2 y with duration >15 d | 4 | 1 (25.0) | 1.05 (0.02–13.80) |
Health care worker during the past 2 y | 4 | 1 (25.0) | 1.05 (0.02–13.80) |
Health sciences student during the past 2 y | 4 | 3 (75.0) | 9.48 (0.71–503.7) |
Prisoner during the past 2 y | 24 | 4 (16.7) | 0.63 (0.20–2.02) |
Adult case with household contact risk factor(s)† | 109 | 56 (51.4) | 3.34 (1.86–6.00) |
Pediatric case with household contact risk factor(s)† | 7 | 3 (42.9) | 2.37 (0.32–14.92) |
Private or self-administered treatment | 87 | 28 (32.2) | 1.50 (0.79–2.83) |
Sputum positive during second or third month of category I treatment | 5 | 3 (60.0) | 4.74 (0.50–58.69) |
Sputum positive during second or third month of category II treatment | 13 | 11 (84.6) | 17.38 (3.36–166.8) |
Failure of category I treatment‡ | 30 | 22 (73.3) | 8.69 (3.44–21.93) |
Relapsed within 6 mo after category I treatment§ | 65 | 26 (40.0) | 2.11 (1.08–4.12) |
Defaulted while receiving category I treatment¶ | 98 | 15 (15.3) | 0.57 (0.28–1.16) |
Failure of category II treatment‡ | 18 | 11 (61.1) | 4.97 (1.74–14.18) |
Relapsed within 6 mo after category II treatment§ | 8 | 5 (62.5) | 5.27 (0.93–35.66) |
Defaulted while receiving category II treatment¶ | 63 | 16 (25.4) | 1.08 (0.52–2.22) |
Chronic treatment (>2 prior treatments)# | 253 | 97 (38.3) | 1.96 (1.17–3.29) |
*MDR, multidrug resistant; TB, tuberculosis; CI, confidence interval; NTP, National Tuberculosis Control Program.
†Household contact risk factors are defined as household contact with a patient with known MDR TB, with a patient who showed TB treatment failure in the past 2 y, or with a patient being treated with second-line TB drugs.
‡Defined as positive smear and/or culture after >4 mo of treatment, or positive smear and/or culture upon finishing treatment.
§Defined as recurrence of disease <6 mo after being classified as cured by NTP norms.
¶Defined as not receiving treatment >1 mo upon enrollment into the study.
#Defined as a history of >2 previous TB treatments.
Page created: July 25, 2011
Page updated: July 25, 2011
Page reviewed: July 25, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.